<DOC>
	<DOCNO>NCT01790451</DOCNO>
	<brief_summary>Up 16 patient confirm low- intermediate risk prostate cancer schedule radical prostatectomy ask Irreversible Electroporation ( IRE ) procedure approximately 30 day prior prostatectomy . Ablation IRE perform use similar planning criterion , procedure protocol , instrument software use brachytherapy , conventional target radiation therapy radioactive seed implant prostate tumour . Patients ultrasound prostate image data enter Planning Software system . The volume prostate measure specified ablation zone determine . The IRE perform general anaesthetic specify zone identify planning stage ablate . Four IRE electrode needle place prostate ultrasound image guidance . When needles place , electric pulse one two minute duration use ablate specify zone . The total procedure time approximately 1 hour . Safety data collect patient follow 1 week , 2 week post IRE , pre- prostatectomy , post prostatectomy 1 week post prostatectomy . The safety data collection 2 week post IRE . Before IRE procedure , patient Magnetic Resonance Imaging ( MRI ) Contrast Enhanced Ultrasound ( CEUS ) prostate . The patient schedule prostatectomy approximately 30 day IRE procedure . Pre-prostatectomy , ablation zone radiologically assess control MRI/CEUS . Post prostatectomy , efficacy ablation determine histological examination prostate Pathology Department measure complete incomplete ablation . The primary outcome safety measure composite procedural device post procedural adverse event , measure Common Terminology Criteria Adverse Events v 4 ( CTCAE ) , Expanded Prostate Cancer Index Composite ( EPIC ) score , International Prostate Symptom Score ( IPSS ) require catheterization time International Index Erectile Function ( IIEF ) efficacy ablation determine histological examination post prostatectomy . Secondary outcome patient procedure satisfaction measure patient satisfaction questionnaire , post procedural pain management Visual Analogue Scale ( VAS ) pain score , time ambulation , length hospital stay .</brief_summary>
	<brief_title>Safety Efficacy Irreversible Electroporation Ablation Prostate Cancer Humans</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Patients prostate cancer indicate undergo radical prostatectomy 2 . Life expectancy &gt; 10 year 3 . Able visualize prostate gland adequately transrectal US image enrolment evaluation 4 . No prostate calcification great 5 mm 5 . Ability subject stop anticoagulant antiplatelet therapy 7 day prior 7 day post procedure 1 . Other Conditions/Status 1 . Bleeding disorder determine prothrombin time ( PT ) &gt; 14.5 second , partial thromboplastin time ( PTT ) &gt; 34 second , Platelet Count &lt; 140/microliter ( uL ) 2 . Active urinary tract infection ( UTI ) 3 . History bladder neck contracture 4 . Anaesthesia Surgical Assignment , category IV great 5 . History inflammatory bowel disease 6 . Concurrent major debilitate illness 7 . Prior concurrent malignancy 8 . Cardiac History 9 . Implantable cardioverterdefibrillator ( ICD ) / Pacemaker 2 . Prior current therapy 1 . Biologic therapy prostate cancer 2 . Chemotherapy prostate cancer 3 . Hormonal therapy prostate cancer within 3 month procedure 4 . Radiotherapy prostate cancer 5 . Transurethral prostatectomy ( TURP ) , urethral stent 6 . Prior major rectal surgery ( except haemorrhoid ) 7 . Inability unwillingness tolerate temporary cessation concurrent anticoagulation therapy antiplatelet drug period 7days prior procedure 7 day procedure</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>focal therapy</keyword>
	<keyword>irreversible electroporation</keyword>
	<keyword>prostate cancer</keyword>
</DOC>